Adjuvants Immunologic Clinical Trials

All Categories Medications / Interventions » Aa » Adjuvants Immunologic

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Condition: Pulmonary Tuberculosis
Interventions: Biological: ID93 + GLA-SE; Biological: ID93 alone
Sponsors: Infectious Disease Research Institute; Infectious Disease Research Institute; Aeras Global TB Vaccine Foundation; Bill and Melinda Gates Foundation; Paul G. Allen Family Foundation
Not yet recruiting - verified May 2012
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Condition: Influenza (Pandemic)
Interventions: Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Saline Placebo
Sponsors: Novavax; Novavax; Department of Health and Human Services
Recruiting - verified May 2012
A/H5N1 VLP Antigen Dose Ranging Study With Adjuvant 1

Condition: Influenza (Pandemic)
Interventions: Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Saline placebo
Sponsors: Novavax; Novavax; Department of Health and Human Services
Recruiting - verified May 2012
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

Condition: Melanoma
Interventions: Biological: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS); Biological: MELITAC 12.1 + Montanide ISA-51 + polyICLC
Sponsors: University of Virginia; University of Virginia; UVA Human Immune Therapy Center; National Cancer Institute (NCI); Oncovir, Inc.
Not yet recruiting - verified April 2012
Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine; Biological: IL-12 pDNA adjuvant; Biological: VSV HIV gag vaccine; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012
Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: Cyclophosphamide; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine; Radiation: Stereotactic Body Radiation (SBRT); Drug: FOLFIRINOX
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified May 2012
H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Condition: Influenza
Interventions: Biological: H5N1 Vaccine; Drug: ASO3 Adjuvant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified March 2012
Immune Responses to H5N1 Vaccine With and Without MF59 Adjuvant

Conditions: Influenza; Healthy
Interventions: Biological: H5N1 vaccine plus MF59 adjuvant; Biological: H5N1 vaccine without adjuvant
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI); Center for Human Immunology, Autoimmunity and Inflammation
Recruiting - verified February 2012
Phase II Intratumoral pIL-12 Electroporation in Cutaneous Lymphoma

Conditions: Cutaneous T Cell Lymphomas (CTCL); Mycosis Fungoides (MF)
Interventions: Drug: IL-12 plasmid; Device: Electroporation
Sponsors: University of California, San Francisco; University of California, San Francisco; OncoSec Medical Incorporated
Not yet recruiting - verified April 2012
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Diseases; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Drug: Fludarabine monophosphate; Drug: Busulfan; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Double Blinded, Placebo Controlled, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Rituximab; Drug: Glatiramer Acetate
Sponsors: University of Colorado, Denver; University of Colorado, Denver; University of Colorado Hospital; Rocky Mountain Multiple Sclerosis Center
Recruiting - verified March 2012
A Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211

Condition: Healthy
Interventions: Drug: TD-1211; Drug: TD-1211+ itraconazole
Sponsors: Theravance; Theravance
Not yet recruiting - verified March 2012
To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS

Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer Acetate; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2012
Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis

Condition: Osteoarthritis, Knee
Interventions: Device: hylan G-F 20; Device: 1% sodium hyaluronate
Sponsors: American Orthopaedic Society for Sports Medicine; American Orthopaedic Society for Sports Medicine; United States Naval Medical Center, Portsmouth
Recruiting - verified March 2012
Improving White Blood Cell Collection From Healthy Donors

Conditions: Blood Donor; Leukocyte Transfusion; Granulocyte Colony-Stimulation Factor; Blood Component Removal
Interventions: Drug: Filgrastim (G-CSF); Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012
Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

Conditions: Vaginal Inflammation; Vaginal Infections
Interventions: Drug: Imiquimod; Drug: HEC Placebo; Drug: Nonoxynol-9
Sponsors: CONRAD; CONRAD
Recruiting - verified May 2012
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Condition: Thrombotic Thrombocytopenic Purpura
Intervention: Biological: rituximab
Sponsors: Washington University School of Medicine; J. Evan Sadler, M.D., Ph.D.
Not yet recruiting - verified March 2012
Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block

Conditions: Shoulder Pain; Injury of Shoulder Region; Disorder of Shoulder; Disorder of Rotator Cuff; Disorder of Tendon of Biceps
Interventions: Drug: Dexamethasone; Drug: Bupivacaine
Sponsors: Lifespan; Lifespan; Tufts Medical Center; United States Naval Medical Center, Portsmouth
Not yet recruiting - verified March 2012
Collection of Transplant Stem Cells for Plasma Cell Myeloma

Condition: Plasma Cell Myeloma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Procedure: Apheresis
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa

Condition: Dystrophic Epidermolysis Bullosa
Intervention: Drug: Granulocyte Colony Stimulating Factor (GCSF)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified February 2012
Filgrastim in Treating Patients With Bortezomib Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: G-CSF and Bortezomib
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012
Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults

Condition: Pneumococcal Vaccines
Interventions: Other: normal saline injection; Biological: SPWCV + alum
Sponsors: Program for Appropriate Technology in Health; PATH Vaccine Solutions
Recruiting - verified February 2012
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Carboplatin; Biological: Autologous stem cell infusion; Biological: Granulocyte colony stimulating factor; Radiation: Radiation therapy; Drug: Isotretinoin (13-cis-retinoic acid); Drug: Melphalan; Drug: Etoposide
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
PharmacoMRI of Parkinson Disease

Condition: Parkinson's Disease
Intervention: Drug: Carbidopa-Levodopa
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012
A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for TMJ

Conditions: Temporomandibular Joint Dysfunction; Pain; Arthrocentesis
Interventions: Drug: Hyaluronic acid; Drug: Corticosteroid; Drug: Lactated Ringers
Sponsors: Emory University; Emory University; University of California, Los Angeles; Oregon Health and Science University; University of Minnesota - Clinical and Translational Science Institute; University of Cincinnati; University of Pennsylvania
Recruiting - verified March 2012
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Conditions: Leukemia; Lymphoma; Myeloma; Myeloproliferative Diseases
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Alemtuzumab; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF; Procedure: Low Dose Donor T-Cells; Procedure: High Dose Donor T-Cells
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Conditions: Chemotherapy-induced Neutropenia; Breast Cancer
Interventions: Drug: LA-EP2006; Drug: Peg-Filgrastim
Sponsors: Sandoz; Sandoz
Recruiting - verified January 2012
Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

Conditions: Parkinson's Disease; Motor Fluctuations
Interventions: Drug: DM-1992; Drug: Sinemet IR
Sponsors: Depomed; Depomed
Recruiting - verified April 2012
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Condition: Breast Cancer
Interventions: Drug: TAC chemotherapy; Drug: TC chemotherapy; Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy; Drug: TCH chemotherapy
Sponsors: Agendia; Agendia; University of South Florida; University of Miami
Recruiting - verified January 2012
Auto Transplant for High Risk or Relapsed Solid Tumor

Conditions: Hematopoietic Stem Cell Transplantation; Solid Tumor; Transplantation, Autologous
Interventions: Drug: Ifosfamide; Drug: Etoposide phosphate; Drug: Mesna; Biological: Granulocyte colony-stimulating factor; Drug: Busulfan; Drug: Melphalan; Drug: Thiotepa; Biological: Autologous stem cell infusion; Radiation: Radiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Trial of pIL-12 Electroporation Malignant Melanoma

Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12; Device: Intratumoral Electroporation
Sponsors: University of California, San Francisco; University of California, San Francisco; OncoSec Medical Incorporated
Recruiting - verified April 2012
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Conditions: Leukemia; Lymphoma
Interventions: Drug: Rituximab; Drug: 111In Ibritumumab; Procedure: Planar Scintigraphy Imaging; Drug: 90Y IbritumumabTiuxetan; Drug: Fludarabine; Drug: Bendamustine; Drug: Thymoglobulin; Drug: Tacrolimus; Drug: Methotrexate; Drug: Mycophenolate; Drug: G-CSF; Procedure: Stem Cell Transplantation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Spectrum Pharmaceuticals, Inc
Not yet recruiting - verified May 2012
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Condition: Autoimmune Disorders
Interventions: Biological: Subcutaneous Immucothel; Biological: subcutaneous Immucothel plus Montanide; Biological: Oral KLH followed by immunization
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified December 2011
Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis

Condition: Knee Osteoarthritis
Interventions: Other: Orthovisc; Device: DonJoy HA lite knee brace; Device: Orthovisc injections and DonJoy HA lite knee brace
Sponsors: OAD Orthopaedics; OAD Orthopaedics
Recruiting - verified May 2012
Cetuximab and Interleukin-12 in Treating Patients With Head and Neck Cancer That is Recurrent, Metastatic, or Cannot Be Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Biological: recombinant interleukin-12; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

Condition: Cocaine Dependence
Interventions: Drug: levodopa carbidopa and entacapone (LCE); Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Not yet recruiting - verified December 2011
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Conditions: Hodgkin Disease; Hodgkin Lymphoma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Drug: Yttrium-Daclizumab (CHX-A Daclizumab); Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Ca(2+)-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Condition: Adenocarcinoma Pancreas
Interventions: Other: Gemcitabine; Drug: CP-870,893
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting - verified March 2012
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat; Drug: lenalidomide
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Celgene Corporation; Novartis
Recruiting - verified February 2012
Study to Assess the Effect of Adjuvant and Route of Administration on the Safety, Tolerability, and Immunogenicity of NDV-3 Vaccine Against S.Aureus and Candida

Conditions: Staphylococcal Infections; Yeast Infections; Candidiasis
Interventions: Biological: NDV-3 vaccine with alum administered IM; Biological: NDV-3 vaccine without alum administered IM; Biological: Placebo administered ID; Biological: NDV-3 vaccine without alum administered ID
Sponsors: NovaDigm Therapeutics, Inc.; NovaDigm Therapeutics, Inc.; Department of Defense
Recruiting - verified October 2011
Functional and Quality of Life Outcomes Following Viscosupplementation for Knee Osteoarthritis

Condition: Knee Osteoarthritis
Intervention: Other: Subject outcomes following viscosupplementation of the knee
Sponsors: University of Florida; University of Florida
Recruiting - verified April 2012
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Condition: Melanoma
Interventions: Drug: MAGE-A3 ASCI injections without Poly IC:LC; Drug: MAGE-A3 ASCI injections with Poly IC:LC
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Oncovir, Inc.
Recruiting - verified March 2012
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

Conditions: Recurrent Neuroendocrine Carcinoma of the Skin; Stage I Neuroendocrine Carcinoma of the Skin; Stage II Neuroendocrine Carcinoma of the Skin; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene; Biological: electroporation-mediated plasmid DNA vaccine therapy; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)

Condition: Malaria
Interventions: Biological: Pfs25-EPA; Biological: Pfs25-EPA/Alhydrogel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012
Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012
Toll-like Receptor (TLR) 7 Agonist and Radiotherapy for Breast Cancer With Skin Metastases

Conditions: Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer
Interventions: Radiation: Radiation; Drug: Imiquimod
Sponsors: New York University School of Medicine; New York University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified April 2012
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
Sponsors: University of Southern California; University of Southern California; Teva Pharmaceuticals USA
Recruiting - verified November 2011
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: lenalidomide; Biological: rituximab; Other: pharmacological study; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Condition: Lymphoma
Interventions: Drug: Vorinostat; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Infusion; Drug: Rituximab; Drug: G-CSF; Drug: Palifermin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of LY2523355 in Patients With Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: LY2523355; Drug: Ixabepilone; Drug: pegfilgrastim; Drug: filgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Conditions: Lymphoma, Diffuse Large-Cell B-cell; Diffuse, Large B-cell Lymphoma; Lymphoma, Diffuse Large-Cell; Large-Cell Lymphoma, Diffuse
Interventions: Drug: MLN4924; Drug: Etoposide; Drug: Prednisone; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Rituximab; Drug: Filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Conditions: Sarcoma; Leiomyosarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Fibrous; Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Intervention: Drug: Gemcitabine and Docetaxel in Combination with Pazopanib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network
Recruiting - verified April 2012
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate

Condition: Multiple Sclerosis
Interventions: Drug: diclofenac sodium topical gel; Other: Placebo
Sponsors: Brown, Theodore R., M.D., MPH; Brown, Theodore R., M.D., MPH; Teva Neuroscience, Inc.
Recruiting - verified October 2011
Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

Condition: Actinic Keratosis
Interventions: Drug: Imiquimod cream 3.75%; Drug: Placebo cream
Sponsors: Medicis Global Service Corporation; Medicis Global Service Corporation
Recruiting - verified April 2012
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: DPX-Survivac; Drug: low dose cyclophosphamide (oral)
Sponsors: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies, Inc.
Recruiting - verified December 2011
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Busulfan Plus Melphalan Versus Melphalan

Condition: Myeloma
Interventions: Drug: Busulfan; Drug: Melphalan; Other: Questionnaire; Drug: G-CSF; Drug: High Dose Melphalan; Procedure: Stem cell transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2012
High-Dose Cyclophosphamide and Anti-Thymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Systemic Scleroderma

Condition: Systemic Scleroderma
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: cyclophosphamide; Biological: anti-thymocyte globulin; Other: questionnaire administration; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Condition: Melanoma
Intervention: Other: recMAGE-A3 + AS15 ASCI
Sponsors: University of Virginia; Craig L Slingluff, Jr; GlaxoSmithKline
Recruiting - verified August 2011
Carbidopa-Levodopa Extended-Release (CD-LD ER) Alone or in Combination With Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by Extension Safety Study of IPX066 in Subjects With Advanced Parkinson's Disease

Condition: Parkinson's Disease
Intervention: Drug: IPX066
Sponsors: IMPAX Laboratories, Inc.; IMPAX Laboratories, Inc.; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified August 2011
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: etoposide; Procedure: leukapheresis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Condition: Glioblastoma
Interventions: Drug: Cyclophosphamide; Biological: IMA950 plus GM-CSF; Biological: IMA950; Drug: Imiquimod
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH; National Cancer Institute (NCI)
Recruiting - verified October 2011
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Biological: Brain tumor initiating cells; Drug: Imiquimod
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified March 2012
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Condition: Multiple Myeloma
Intervention: Biological: recMAGE-A3 Protein plus AS15 Adjuvant
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; GlaxoSmithKline
Recruiting - verified May 2012
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Conditions: Hookworm Infection; Hookworm Disease
Interventions: Biological: 10 μg Na-GST-1/Alhydrogel; Biological: 30 μg Na-GST-1/Alhydrogel; Biological: 100 μg Na-GST-1/Alhydrogel; Biological: 10 μg Na-GST-1/Alhydrogel with 1 μg GLA-AF; Biological: 30 μg Na-GST-1/Alhydrogel with 1 μg GLA-AF; Biological: 100 μg Na-GST-1/Alhydrogel with 1 μg GLA-AF; Biological: 10 μg Na-GST-1/Alhydrogel with 5 μg GLA-AF; Biological: 30 μg Na-GST-1/Alhydrogel with 5 μg GLA-AF; Biological: 100 μg Na-GST-1/Alhydrogel with 5 μg GLA-AF
Sponsors: Albert B. Sabin Vaccine Institute; Albert B. Sabin Vaccine Institute; Children's Research Institute; George Washington University
Recruiting - verified May 2012
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

Condition: SARS
Interventions: Drug: Aluminum hydroxide adjuvant (Alhydrogel®); Other: Phosphate buffered saline Placebo; Biological: Recombinant S protein SARS vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: bacilli calmette-guerin (BCG); Drug: lenalidomide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified April 2012
Arry-520 + Carfilzomib for Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Arry-520; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Array BioPharma; Onyx Therapeutics, Inc.
Recruiting - verified February 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Condition: Lung Cancer
Intervention: Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Tumor Cell Vaccines and ISCOMATRIX(Trademark) With Chemotherapy After Tumor Removal

Conditions: Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor; Drug: Cyclophosphamide; Drug: Celecoxib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Hormonal Therapy for Teens With Anorexia Nervosa

Condition: Anorexia Nervosa (AN)
Interventions: Drug: DHEA (Prasterone) + ERT (Aviane); Other: Placebo
Sponsors: Children's Hospital Boston; Children's Hospital Boston
Recruiting - verified May 2012
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Conditions: Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions: Drug: Plerixafor; Drug: Filgrastim
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012
Stem Cell Collection With Ofatumumab

Condition: Lymphoma
Interventions: Drug: Ofatumumab; Drug: Ifosfamide; Drug: Etoposide; Drug: Mesna; Drug: G-CSF; Procedure: Stem Cell Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified April 2012
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia

Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Filgrastim, Ifosfamide, Etoposide, Dexamethasone, Mesna
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Condition: Her2normal
Intervention: Drug: eribulin mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified February 2012
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gene Therapy for Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: filgrastim; Drug: plerixafor; Procedure: leukapheresis; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine

Conditions: Immunological Stimulation; Attenuated Vaccine
Intervention: Biological: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012
Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Biological: FANG; Drug: standard of care observational follow-up
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

Condition: Pegfilgrastim-induced Back and Leg Pain
Interventions: Drug: Loratadine; Drug: placebo
Sponsors: University of Vermont; University of Vermont; Cancer and Leukemia Group B
Recruiting - verified March 2012
Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Stage II Esophageal Cancer
Interventions: Biological: panitumumab; Drug: oxaliplatin; Drug: leucovorin calcium; Drug: fluorouracil; Radiation: radiation therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: high performance liquid chromatography; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: pharmacological study; Other: pharmacogenomic studies
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified July 2011
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Condition: Refractory Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

Conditions: Grade IV Glioma; Grade IV Astrocytoma; Glioblastoma Multiforme
Intervention: Biological: TVI-Brain-1
Sponsors: TVAX Biomedical; TVAX Biomedical
Recruiting - verified April 2012
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Radiation: 3D-RT or IMRT
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified March 2012
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers

Condition: Healthy Volunteers
Intervention: Drug: Poly ICLC
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified January 2012
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Chronic Discogenic Lumbar Back Pain

Condition: Degenerative Disc Disease
Interventions: Biological: Single Dose MPCs Injection; Biological: Single Dose MPCs Injection; Procedure: Single injection of saline solution; Procedure: Single injection of hyaluronic acid
Sponsors: Mesoblast, Ltd.; Mesoblast, Ltd.
Recruiting - verified August 2011
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Conditions: Leukemia; Lymphoma; Neuroblastoma; Sarcoma; Desmoplastic Small Round Cell Tumor
Interventions: Drug: Melphalan; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: Etoposide; Drug: Filgrastim; Biological: NK-DLI Infusions
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas

Conditions: Low Grade Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Oligoastrocytoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy

Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF; Biological: Montanide adjuvant + GM-CSF
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Department of Defense
Recruiting - verified March 2012
Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

Conditions: Mesolthelioma; Esophageal Cancer; Lung Cancer
Interventions: Drug: Celecoxib; Drug: ISCOMATRIX (TM) Adjuvant; Biological: Autologous Tumor Cell Vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

Condition: Melanoma
Interventions: Biological: MELITAC 12.1; Drug: Imiquimod
Sponsors: University of Virginia; University of Virginia
Recruiting - verified January 2012
Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine; Biological: IL-12; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: topotecan hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH
Recruiting - verified May 2012
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Conditions: Fallopian Tubes; Ovarian Cancer; Peritoneal Cancer
Intervention: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012
Post-op Treatment With Hyaluronic Acid Injections

Conditions: Meniscus Tear; Chondropathy/Degenerative Joint Disease (DJD)
Interventions: Device: Euflexxa; Other: Saline
Sponsors: The Hawkins Foundation; The Hawkins Foundation; Ferring Pharmaceuticals
Recruiting - verified July 2011
Survivin Vaccine Therapy for Patients With Malignant Gliomas

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor
Interventions: Drug: Montanide ISA-51/survivin peptide vaccine; Biological: sargramostim; Other: flow cytometry; Other: laboratory biomarker analysis; Other: immunoenzyme technique
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Not yet recruiting - verified January 2012
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

Conditions: Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma
Intervention: Biological: Autologous dendritic cell vaccine with adjuvant
Sponsors: Penn State University; Penn State University; Solving Kids’ Cancer
Recruiting - verified January 2012
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Conditions: Clostridium Difficile Infection; Diarrhea
Interventions: Biological: Clostridium difficile toxoids A and B (Low-dose with adjuvant); Biological: Clostridium difficile toxoids A and B (Low-dose without adjuvant); Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant); Biological: Clostridium difficile toxoids A and B (high-dose without adjuvant); Biological: Placebo: 0.9% normal saline
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses

Condition: Actinic Keratosis
Interventions: Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm; Drug: Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
Sponsors: Frankel, Amylynne, M.D.; Frankel, Amylynne, M.D.; Graceway Pharmaceuticals, LLC
Recruiting - verified June 2011
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Conditions: Lung Cancer; Non Small Cell Lung Carcinoma; Hypermethylation
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Drug: Vidaza; Procedure: Tumor Specimen for Methylation Analysis; Procedure: Blood Sample for Methylation Analysis; Drug: Vinorelbine; Drug: Docetaxel; Drug: Pemetrexed
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified October 2011
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

Condition: Pancreatic Adenocarcinoma
Intervention: Drug: Intraperitoneal Gemcitabine
Sponsors: Washington Hospital Center; Washington Hospital Center
Recruiting - verified April 2012
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Condition: Actinic Keratosis
Interventions: Drug: Imiquimod/photodynamic therapy; Drug: Imiquimod only
Sponsors: Tennessee Clinical Research Center; Tennessee Clinical Research Center; Graceway Pharmaceuticals, LLC
Recruiting - verified July 2011
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Stage IV Melanoma That Has Been Removed By Surgery

Condition: Melanoma (Skin)
Interventions: Biological: MART-1:26-35(27L) peptide vaccine; Biological: NY-ESO-1 peptide vaccine; Biological: anti-PD-1 human monoclonal antibody MDX-1106; Biological: gp100:209-217(210M) peptide vaccine; Biological: gp100:280-288(288V) peptide vaccine; Drug: Montanide ISA 51 VG; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified September 2011
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Doxorubicin; Drug: Bortezomib; Drug: Bendamustine; Drug: Filgrastim
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Cephalon
Recruiting - verified March 2012
Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Condition: Septicemia
Interventions: Biological: CPG 7909; Drug: Placebo; Biological: J5-OMP Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Drug: Gemcitabine and cisplatin; Drug: Gemcitabine / Cisplatin
Sponsors: Emory University; Emory University
Recruiting - verified May 2012
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim) plus Plerixafor Injection; Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors: Genzyme; Genzyme
Recruiting - verified April 2012
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Condition: Sarcoma
Interventions: Biological: Trivalent ganglioside vaccine; Biological: OPT-821
Sponsors: MabVax Therapeutics, Inc.; MabVax Therapeutics, Inc.
Recruiting - verified March 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Conditions: Lung Cancer; Esophageal Cancer; Malignant Pleural Mesothelioma; Thymoma; Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562); Drug: Celecoxib; Drug: cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Exercise as an Adjuvant to Aphasia Therapy

Condition: Aphasia
Interventions: Behavioral: Aphasia therapy for anomia; Behavioral: Aerobic exercise; Behavioral: Stretching
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Brooks Rehabilitation Clinical Research Center
Recruiting - verified December 2011
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: dexamethasone; Biological: filgrastim; Procedure: leukapheresis; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Reversing Type 1 Diabetes After it is Established

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Anti-Thymocyte Globin plus pegylated GCSF; Drug: Placebo
Sponsors: University of Florida; University of Florida; The Helmsley Charitable Trust; Genzyme
Recruiting - verified February 2012
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia; Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: Biological: filgrastim; Drug: clofarabine; Drug: cytarabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Recurrent Intraocular Melanoma
Interventions: Biological: recombinant interferon alfa-2b; Drug: dacarbazine; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified December 2011
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: filgrastim; Drug: plerixafor; Biological: rituximab; Drug: ifosfamide; Drug: carboplatin; Drug: etoposide; Procedure: leukapheresis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Condition: Aneurysmal Subarachnoid Hemorrhage
Interventions: Drug: Tiopronin for Hunt Hess grades I-III; Drug: Placebo for Hunt Hess grades I-III; Drug: Placebo for Hunt Hess grades IV-V; Drug: Tiopronin for Hunt Hess grades IV-V
Sponsors: Columbia University; Columbia University; University of Florida; University of Washington
Recruiting - verified January 2012
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: cyclophosphamide; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndromes
Interventions: Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified March 2012
HAI Abraxane With Gemcitabine and Bevacizumab

Condition: Advanced Cancers
Interventions: Drug: HAI Abraxane; Drug: Gemcitabine; Drug: Bevacizumab; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)

Condition: Multiple Sclerosis
Interventions: Drug: ACTH; Drug: Methylprednisolone
Sponsors: University of Southern California; University of Southern California; Questcor Pharmaceuticals, Inc.
Recruiting - verified July 2011
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Conditions: Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide; Drug: Etoposide; Drug: Alemtuzumab; Drug: Doxorubicin; Drug: Prednisone; Drug: Filgrastim; Drug: Rituximab; Drug: Vincristine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Acute Promyelocytic Leukemia (M3); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: filgrastim; Procedure: ex-vivo umbilical cord blood expansion; Other: DNA analysis; Procedure: bone marrow aspiration; Genetic: cytogenetic analysis; Other: flow cytometry; Other: fluorescence in situ hybridization; Other: laboratory biomarker analysis; Drug: clofarabine; Procedure: ex vivo-expanded cord blood progenitor cell infusion
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: tacrolimus; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: laboratory biomarker analysis; Procedure: flow cytometry; Radiation: total-body irradiation; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Procedure: polymerase chain reaction; Biological: filgrastim
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

Condition: Stem Cell Transplant Patients
Intervention: Drug: G-CSF +/- AMD3100
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma

Conditions: Thymoma; Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
MUC1 Vaccine for Triple-negative Breast Cancer

Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Conditions: Atrophic Vaginitis; Breast Cancer
Intervention: Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors

Conditions: Central Nervous System Embryonal Tumor; Germ Cell Tumors
Interventions: Drug: Melphalan; Drug: Carboplatin; Drug: Sodium thiosulfate; Drug: Filgrastim; Drug: Pegfilgrastim
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute
Recruiting - verified January 2012
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: CTX-100 (formerly ETX-100) (hyaluronic acid)
Sponsors: Turino, Gerard, M.D.; Turino, Gerard, M.D.
Recruiting - verified June 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
The Effects of Aldara as an Adjunct to Laser Treatment

Condition: Port Wine Stains
Interventions: Drug: Imiquimod (Aldara); Drug: non-medicated petroleum cream
Sponsors: University of Kentucky; University of Kentucky; Graceway Pharmaceuticals, LLC
Recruiting - verified October 2011
Multisite Controlled Trial of Cocaine Vaccine

Condition: Cocaine Dependence
Interventions: Drug: TA-CD Vaccination; Other: Placebo Injection
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institute on Drug Abuse (NIDA); US Department of Veterans Affairs Cooperative Studies Program; VA Maryland Health Care System; Columbia University; VA New York Harbor Healthcare System; University of Pennsylvania; Johns Hopkins University; University of Cincinnati; Celtic Pharma Development Services
Recruiting - verified September 2011
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified November 2011
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Condition: Bladder Cancer
Interventions: Drug: Mitomycin C (MMC); Biological: Bacillus Calmette-Guerin (BCG)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012
Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Erlotinib; Drug: capecitabine; Radiation: Radiation Therapy; Drug: gemcitabine; Drug: erlotinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Genentech
Recruiting - verified April 2012
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Condition: Alzheimer Disease
Intervention: Drug: ACC-001+ QS21
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified April 2012
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Conditions: Acute Myelogenous Leukemia; Leukemia
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Genzyme; Onyx Pharmaceuticals
Recruiting - verified February 2012
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel; Drug: trastuzumab; Drug: Doxorubicin; Drug: cyclophosphamide
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Conditions: MonoMAC; Myelodysplastic Syndrome; Immunodeficiency
Interventions: Procedure: Reduced-Intensity Hematopoietic Stem Cell; Drug: Fludarabine; Procedure: Total Body Irradiation (TBI); Drug: Filgrastim; Drug: Sirolimus; Drug: Tacrolimus; Drug: Ursodiol
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine (Gemzar), docetaxel (Taxotere), and capecitabine (Xeloda)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Conditions: Stem Cell Transplantation; Leukemia; Lymphoma
Interventions: Drug: Thiotepa; Drug: Clofarabine; Drug: Busulfan; Procedure: Allogeneic Stem Cell Transplantation; Drug: Thymoglobulin (ATG); Drug: G-CSF (Filgrastim)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Neo-Adjuvant FOLFOX for Rectal Carcinoma

Condition: Rectal Neoplasms
Interventions: Drug: FOLFOX; Procedure: total mesorectal excision (TME)
Sponsors: Beth Israel Medical Center; Beth Israel Medical Center; St. Luke's-Roosevelt Hospital Center
Recruiting - verified January 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer
Interventions: Drug: imiquimod; Drug: Abraxane; Other: laboratory biomarker analysis; Genetic: RNA analysis; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias

Condition: Acute Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Cytarabine; Drug: G-CSF (Filgrastim, Neupogen); Drug: Idarubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Conditions: Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: GM-CSF; Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: imiquimod
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified October 2011
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified February 2012
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Proton Therapy for Resectable Carcinoma of the Pancreas

Condition: Pancreatic Cancer
Intervention: Radiation: Proton Therapy, Capecitabine, Gemcitabine
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2012
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

Condition: Pancreatic Cancer
Interventions: Biological: GVAX pancreatic cancer vaccine; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

Condition: Stroke
Interventions: Drug: Sinemet, ritalin, amphetamine, and placebo; Device: Transcranial magnetic stimulation (TMS); Other: Combined drug treatment and TMS
Sponsors: Emory University; Emory University; National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Condition: Prostate Cancer
Intervention: Biological: peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
High-Dose Melphalan and Stem Cell Transplant in Treating Patients With Immunoglobulin Deposition Disease or Light-Chain Deposition Disease

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified February 2012
Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Drug: temozolomide; Drug: carmustine; Radiation: radiation therapy; Procedure: autologous hematopoietic stem cell transplantation; Drug: O6-benzylguanine; Biological: filgrastim; Procedure: in vitro-treated peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Conditions: Multiple Myeloma; Primary Amyloidosis
Interventions: Drug: Melphalan; Procedure: Stem Cell Infusion; Behavioral: Questionnaires; Drug: Granulocyte-colony stimulating factor (G-CSF); Procedure: Apheresis
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Conditions: Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: melphalan; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation; Other: pharmacological study; Procedure: autologous bone marrow transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011
Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: hematopoietic stem cell transplantation; Drug: methylprednisolone; Drug: filgrastim; Drug: cyclosporine; Drug: Mycophenolate Mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Liver Cancer; Retinoblastoma; Sarcoma
Interventions: Biological: filgrastim; Drug: busulfan; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: thiotepa; Procedure: stem cell transplantation; Procedure: positron emission tomography; Radiation: tomotherapy; Radiation: total marrow irradiation; Drug: Mesna; Radiation: Whole lung radiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2011
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Condition: Breast Cancer
Interventions: Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: Interleukin-12; Drug: Interleukin-12
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Harvard University; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified October 2011
T Lymphocytes in Treating Patients Undergoing a Donor Bone Marrow Transplant

Condition: Cancer
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: immunological diagnostic method; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009
Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

Conditions: Adenocarcinoma of the Pancreas; Stage IA Pancreatic Cancer; Stage IB Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: docetaxel; Drug: capecitabine; Radiation: intensity-modulated radiation therapy; Drug: oxaliplatin; Procedure: pancreatic surgical procedure; Procedure: therapeutic conventional surgery
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
PET Imaging of P-glycoprotein Function Using [11C]dLop

Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified April 2012
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Conditions: Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate; Drug: paclitaxel; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: filgrastim; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy

Condition: Graft Versus Host Disease
Interventions: Biological: filgrastim; Drug: cyclophosphamide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Cyclophosphamide; Drug: Carmustine; Drug: Etoposide; Drug: Filgrastim; Drug: Antithymocyte globulin; Drug: Cyclosporine; Drug: Mycophenolate mofetil; Drug: rituximab
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Condition: Psoriasis
Interventions: Drug: Imiquimod; Drug: Clobetasol (glucosteroid); Device: Excimer laser (UVB light) treatment
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; University Hospital Case Medical Center
Recruiting - verified February 2012
Phase II Trial of Pulsed Paclitaxel With Concurrent Thoracic Radiotherapy, and Adjuvant Gemcitabine and Carboplatin in Stage IIIA and IIIB Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Taxol (paclitaxel); Procedure: Radiotherapy; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Leo W. Jenkins Cancer Center; Leo W. Jenkins Cancer Center
Recruiting - verified January 2012
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Conditions: Childhood Germ Cell Tumor; Ovarian Cancer; Teratoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Drug: paclitaxel; Drug: thiotepa; Procedure: autologous hematopoietic stem cell transplantation; Drug: Mesna; Biological: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing measles virus; Genetic: fluorescence in situ hybridization; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: needle biopsy; Procedure: neoadjuvant therapy
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: IFN-β-1a (Rebif®)
Sponsors: Waukesha Memorial Hospital; Waukesha Memorial Hospital; The Cleveland Clinic
Recruiting - verified May 2008
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Neurotropin to Treat Fibromyalgia

Condition: Fibromyalgia
Intervention: Drug: Neurotropin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Nursing Research (NINR)
Recruiting - verified October 2011
Combination Chemotherapy Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: melphalan; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: lyso-thermosensitive liposomal doxorubicin; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

Conditions: Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelofibrosis; MDS; Refractory Anemia; Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Multiple Myeloma; Non-Hodgkin's Lymphoma; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Etoposide phosphate; Drug: Melphalan; Drug: Carboplatin; Drug: Sodium thiosulfate; Drug: Filgrastim; Drug: Pegfilgrastim
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Conditions: Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: stem cell transplantation; Radiation: total-body irradiation; Drug: methylprednisolone; Drug: allopurinol; Drug: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Biological: Hematopoietic stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome

Condition: Hematologic Malignancies
Intervention: Drug: Granulocyte Colony Stimulating Factor
Sponsors: Emory University; Emory University
Recruiting - verified November 2011
Treatment of Orthostatic Hypotension in Autonomic Failure

Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
Autologous Transplant for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide + Mesna; Drug: Melphalan; Biological: Granulocyte-colony stimulating factor; Drug: Dexamethasone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Stem Cell Transplantation for Hematological Malignancies

Conditions: Leukemia, Lymphocytic, Acute; AML; MDS
Interventions: Procedure: Stem Cell Transplant; Drug: Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011
Stem Cell Transplant for Hemoglobinopathy

Conditions: Sickle Cell Disease; Thalassemia; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Shwachman-Diamond Syndrome
Interventions: Drug: Busulfan, Fludarabine, ATG, TLI; Drug: Busulfan, Cyclophosphamide, ATG, GCSF; Drug: Campath, Fludarabine, Cyclophosphamide; Radiation: Total Body Irradiation; Procedure: Stem cell infusion
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Marrow Donor Program
Recruiting - verified April 2012
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Taxotere; Drug: Adriamycin/Cytoxan; Drug: docetaxol; Drug: doxorubicin
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Baylor College of Medicine
Recruiting - verified November 2011
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2008
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study

Condition: Pancreatic Neoplasms
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Condition: Healthy
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Conditions: AIDS Related Lymphoma; HIV Infection
Interventions: Biological: Rituximab; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Neurotropin to Treat Chronic Neuropathic Pain

Conditions: CRPS-II (Causalgia); CRPS-I Reflex Sympathetic Dystrophy
Intervention: Drug: Neurotropin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Nursing Research (NINR)
Recruiting - verified July 2011
N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: buthionine sulfoximine; Drug: melphalan; Procedure: Peripheral blood stem cell infusion; Other: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Mast Cell Precursors

Condition: Mastocytosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Conditions: Graft vs Host Disease; Healthy; Lymphopenia
Intervention: Drug: G-CSF
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2011
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Condition: Non Hodgkin's Lymphoma
Interventions: Biological: filgrastim; Biological: Rituximab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011